奥西默提尼布作为复发性肺癌患者的第一线治疗EGFR突变
Atsushi Osoegawa1, Takashi Karashima1, Yohei Takumi1
1Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Japan.
Journal of thoracic disease
|November 16, 2023
概括
奥西默提尼布在肺癌复发中显示出有效性,即使是脑转移. 然而,表现不佳的状态和大脑转移表明,尽管治疗,预后更差,支持其使用,除非禁忌.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 对EGFR突变肺癌的奥西默蒂尼布的辅助使用是有争议的,原因是基于无病生存期 (DFS) 而不是总生存期 (OS) 的批准.
- 本病例系列研究了osimertinib在初始治疗后出现复发的患者的疗效和安全性.
研究的目的:
- 分析EGFR突变肺癌手术后患者的复发模式和奥西默蒂尼布的有效性.
- 在现实环境中评估使用 osimertinib 的安全性和治疗持续时间 (DoT).
主要方法:
- 对20名接受一线奥西默提尼布治疗术后复发的患者进行了回顾性分析 (2018年9月 - 2023年1月).
- 收集的数据包括临床病理因素,DoT和不良事件.
主要成果:
- EGFR突变包括L858R (11名患者) 和外基因19删除 (8名患者).
- 脑转移或表现不佳状态 (PS) 的患者的DoT时间较短.
- 三名患有症状的大脑/脑膜内膜转移的患者尽管初始反应仍死亡;五人因不良事件而停止治疗.
结论:
- 奥西默提尼布显示出疾病的控制,包括在脑转移或不良PS的患者中.
- 大脑转移或不良PS的存在与更差的预后有关,即使是用 osimertinib.
- 辅助性奥西默蒂尼布 (osimertinib) 推用于符合条件的患者,除非有禁忌.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
176
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
171
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
171


